Morgan Stanley raised the firm’s price target on Tandem Diabetes (TNDM) to $17 from $13 and keeps an Equal Weight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes receives FDA clearance for use with Android smartphones
- Tandem Diabetes Care Q3 2025 Earnings: Record Sales & Growth
- Tandem Diabetes price target raised to $16 from $15 at Stifel
- Tandem Diabetes price target raised to $16 from $14 at Goldman Sachs
- Tandem Diabetes price target raised to $18 from $16 at Mizuho